ELV · Insider Trading
Elevance Health, Inc.
Every open-market purchase and sale reported by ELV officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-06 | Mark Kaye | EVP & CFO | MIXED | −1,534 | −$1.61M |
| 2026-09-04 | Erin M Wessling | EVP & Chief Legal Officer | F | −349 | −$143.92K |
| 2026-09-04 | Ryan R Craig | EVP & Chief HR Officer | F | −144 | −$58.44K |
| 2026-07-17 | Gail Boudreaux | President and CEO | Buy | +2,725 | +$1.00M |
| 2026-07-17 | Ramiro G Peru | Director | Buy | +1,000 | +$366.05K |
| 2026-06-15 | Ronald W Penczek | CAO & Controller | Sell | −369 | −$148.77K |
| 2026-06-12 | Robert L Dixon JR | Director | Sell | −151 | −$60.67K |
| 2026-05-20 | Ronald W Penczek | CAO & Controller | MIXED | — | −$166.61K |
| 2026-05-15 | Steven H Collis | Director | A | +563 | — |
| 2026-05-15 | Susan D. DeVore | Director | A | +563 | — |
| 2026-05-15 | Robert L Dixon JR | Director | A | +563 | — |
| 2026-05-15 | Lewis Hay III | Director | A | +563 | — |
| 2026-05-15 | Bahija Jallal | Director | A | +563 | — |
| 2026-05-15 | Antonio F Neri | Director | A | +563 | — |
| 2026-05-15 | Ramiro G Peru | Director | A | +563 | — |
| 2026-05-15 | Ryan M. Schneider | Director | A | +563 | — |
| 2026-05-15 | Amy W Schulman | Director | A | +563 | — |
| 2026-05-15 | Deanna D Strable-Soethout | Director | A | +563 | — |
| 2026-03-23 | Amy W Schulman | Director | Sell | −26 | −$7.47K |
| 2026-03-09 | Charles Morgan Kendrick JR | EVP & President, Commercial | Sell | −3,196 | −$910.60K |
| 2026-03-06 | Steven H Collis | Director | Buy | +3,000 | +$869.52K |
| 2026-03-04 | Gail Boudreaux | President and CEO | MIXED | +18,231 | −$2.47M |
| 2026-03-04 | Mark Kaye | EVP & CFO | MIXED | +15,955 | −$179.96K |
| 2026-03-04 | Peter D Haytaian | EVP & Pres Carelon & CarelonRx | MIXED | +1,218 | −$479.86K |
| 2026-03-04 | Charles Morgan Kendrick JR | EVP & President, Commercial | MIXED | +4,871 | −$488.76K |
| 2026-03-04 | Ratnakar Lavu | EVP & Chief Digital Info Ofr | MIXED | +11,366 | −$155.69K |
| 2026-03-04 | Felicia F Norwood | EVP &Chief Health Benefits Ofr | MIXED | +6,899 | −$558.75K |
| 2026-03-04 | Ryan R Craig | EVP & Chief HR Officer | MIXED | +2,642 | −$95.12K |
| 2026-03-04 | Erin M Wessling | EVP & Chief Legal Officer | MIXED | +2,559 | −$118.44K |
| 2026-03-04 | Ronald W Penczek | CAO & Controller | MIXED | +2,225 | −$49.03K |
| 2026-02-03 | Ryan R Craig | EVP & Chief HR Officer | F | −279 | −$95.37K |
| 2026-02-03 | Amy W Schulman | Director | A | +218 | — |
| 2025-10-03 | Mark Kaye | EVP & CFO | F | −2,895 | −$984.99K |
| 2025-09-05 | Erin M Wessling | EVP & Chief Legal Officer | F | −152 | −$48.88K |
| 2025-09-04 | Ryan R Craig | EVP & Chief HR Officer | A | +970 | — |
| 2025-09-04 | Erin M Wessling | EVP & Chief Legal Officer | A | +931 | — |
| 2025-08-21 | Susan D. DeVore | Director | Buy | +1,200 | +$374.58K |
| 2025-08-05 | Steven H Collis | Director | A | +639 | — |
| 2025-07-18 | Gail Boudreaux | President and CEO | Buy | +8,500 | +$2.44M |
| 2025-05-16 | R Kerry Clark | Director | A | +601 | — |
| 2025-05-16 | Susan D. DeVore | Director | A | +601 | — |
| 2025-05-16 | Robert L Dixon JR | Director | A | +601 | — |
| 2025-05-16 | Lewis Hay III | Director | A | +601 | — |
| 2025-05-16 | Bahija Jallal | Director | A | +601 | — |
| 2025-05-16 | Antonio F Neri | Director | A | +601 | — |
| 2025-05-16 | Ramiro G Peru | Director | A | +601 | — |
| 2025-05-16 | Ryan M. Schneider | Director | A | +601 | — |
| 2025-05-16 | Deanna D Strable-Soethout | Director | A | +601 | — |
| 2025-04-25 | Mark Kaye | EVP & CFO | Sell | −4,588 | −$1.95M |
| 2025-03-11 | Ronald W Penczek | CAO & Controller | Sell | −443 | −$183.90K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Gail Boudreaux | President and CEO | 169,991 | $73.80M |
| Felicia F Norwood | EVP &Chief Health Benefits Ofr | 36,469 | $15.83M |
| Mark Kaye | EVP & CFO | 27,876 | $12.10M |
| Peter D Haytaian | EVP & Pres Carelon & CarelonRx | 24,803 | $10.77M |
| Blair Williams Todt | EVP, CLO & CAO | 15,631 | $6.79M |
| Lewis Hay III | Director | 12,070 | $5.24M |
| Charles Morgan Kendrick JR | EVP & President, Commercial | 11,791 | $5.12M |
| Ramiro G Peru | Director | 10,908 | $4.74M |
| Robert L Dixon JR | Director | 10,734 | $4.66M |
| R Kerry Clark | Director | 9,640 | $4.19M |
| Erin M Wessling | EVP & Chief Legal Officer | 7,230 | $3.14M |
| Ryan M. Schneider | Director | 7,163 | $3.11M |
| Ryan R Craig | EVP & Chief HR Officer | 6,530 | $2.83M |
| Antonio F Neri | Director | 5,488 | $2.38M |
| Bahija Jallal | Director | 5,351 | $2.32M |
| Ratnakar Lavu | EVP & Chief Digital Info Ofr | 4,468 | $1.94M |
| Steven H Collis | Director | 4,202 | $1.82M |
| Susan D. DeVore | Director | 4,065 | $1.76M |
| Ronald W Penczek | CAO & Controller | 3,740 | $1.62M |
| Deanna D Strable-Soethout | Director | 2,209 | $958.99K |
| Amy W Schulman | Director | 781 | $339.06K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ELV quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.